Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work

BACKGROUND: Therapies may be more efficacious when targeting a patient subpopulation with specific attributes, thereby enhancing the cost-effectiveness of treatment. In the CRYSTAL study, patients with metastatic colorectal cancer (mCRC) were treated with cetuximab plus FOLFIRI or FOLFIRI alone unti...

Descripción completa

Detalles Bibliográficos
Autores principales: Harty, Gerard, Jarrett, James, Jofre-Bonet, Mireia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028886/
https://www.ncbi.nlm.nih.gov/pubmed/29948926
http://dx.doi.org/10.1007/s40258-018-0395-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028886/
https://www.ncbi.nlm.nih.gov/pubmed/29948926
http://dx.doi.org/10.1007/s40258-018-0395-5

Ejemplares similares